TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2715089

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.15 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 23489

Group type: EXPERIMENTAL
Intervention: Clorazepate (15 mg at night)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Diazepam (5 mg three times a day)
Number of subjects: 54
Study: 29262751

Group type: EXPERIMENTAL
Intervention: High compression pressure >45 mmHg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Moderate compression pressure 35-40 mmHg
Number of subjects: 102
Study: 27842548

Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization (CR)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Staged complete revascularization (CR)
Number of subjects: 93
Study: 25037854

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) concentrations <8 mg/l
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) concentrations 8-19 mg/l
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) concentrations >20 mg/l
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 312
Study: 22643937

Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Number of subjects: 62

Group type: COMPARATOR
Intervention: Levobupivacaine solution
Number of subjects: 62
Study: 19897236

Group type: EXPERIMENTAL
Intervention: Early sexual debut (first heterosexual intercourse)
Number of subjects: 5131
Study: 19256180

Group type: EXPERIMENTAL
Intervention: Patients treated for hypertension
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Patients with blood pressure below goal
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Individuals treated by a solo provider
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Undiagnosed hypertension
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Diagnosed hypertension
Number of subjects: 1763
Study: 16200335

Group type: COMPARATOR
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metformin (1 g/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study: 15600197

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no rhGH)
Number of subjects: 60
Study: 10801179

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spirits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beer
Number of subjects: 0
Study: 8991488

Group type: EXPERIMENTAL
Intervention: MK-462 IV doses of 5-90 micrograms kg-1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-462 IV doses of 60-90 micrograms kg-1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-462 oral 40 mg tablet without breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-462 oral 40 mg tablet with standard breakfast
Number of subjects: 12
Study: 1481177

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 2 l/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 4 l/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 6 l/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline unburdened walk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Portable gas supply
Number of subjects: 30
Study: 3922282

Group type: EXPERIMENTAL
Intervention: gamma-vinyl GABA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 28631423

Group type: EXPERIMENTAL
Intervention: Pet ownership
Number of subjects: 0
Study: 27793125

Group type: EXPERIMENTAL
Intervention: 12-month telephone-delivered weight loss intervention targeting diet and physical activity
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 156
Study: 24931591

Group type: EXPERIMENTAL
Intervention: Fio2 of 0.14 to 0.15 (average target altitude 3043 m)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group with Fio2 of 0.209
Number of subjects: 76
Study: 21904248

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 20434051

Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage (ICH)
Number of subjects: 1604

Group type: COMPARATOR
Intervention: Ischemic stroke
Number of subjects: 1604
Study: 18695809

Group type: EXPERIMENTAL
Intervention: Liquid petroleum jelly (30 ml applied in the perineal region during the expulsive period)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Liquid petroleum jelly
Number of subjects: 38
Study: 15991506

Group type: EXPERIMENTAL
Intervention: Remifentanil with a small dose of piritramide (0.1 mg kg(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl-based protocol
Number of subjects: 40
Study: 12027845

Group type: EXPERIMENTAL
Intervention: ondansetron 16 mg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: tropisetron 5 mg
Number of subjects: 179

Group type: COMPARATOR
Intervention: metoclopramide 10 mg
Number of subjects: 179
Study: 10464529

Group type: EXPERIMENTAL
Intervention: Hypertonic saline group (HSG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isotonic saline group (ISG)
Number of subjects: 50
Study: 8815566

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) nadroparin with graduated compression stockings
Number of subjects: 241

Group type: COMPARATOR
Intervention: Graduated compression stockings alone (Control)
Number of subjects: 241
Study: 1867297

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 56
Study: 6618119

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 40
Study: 30696483

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 4 weeks (IXEQ4W)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks (IXEQ2W)
Number of subjects: 679

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Patients who resolved enthesitis
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Patients who did not resolve enthesitis
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Patients who resolved dactylitis
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Patients who did not resolve dactylitis
Number of subjects: 679
Study: 28266821

Group type: EXPERIMENTAL
Intervention: Amoxapine (50 mg daily for 4 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vitamin B12 (500 μg three-times daily for 4 weeks)
Number of subjects: 26
Study: 26344392

Group type: EXPERIMENTAL
Intervention: High FIS therapists
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low FIS therapists
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All clients treated by therapists
Number of subjects: 65

Group type: COMPARATOR
Intervention: Silent control group
Number of subjects: 65
Study: 24912615

Group type: EXPERIMENTAL
Intervention: Endoscopically-assisted selective neck dissection (SND)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional selective neck dissection (SND)
Number of subjects: 44
Study: 22836352

Group type: EXPERIMENTAL
Intervention: Cerecyte coils
Number of subjects: 500

Group type: COMPARATOR
Intervention: Bare platinum coils
Number of subjects: 500
Study: 19673086

Group type: EXPERIMENTAL
Intervention: High frequency (HF) rTMS over the left DLPFC
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo rTMS over the left DLPFC
Number of subjects: 16
Study: 17619558

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1365
Study: 15757012

Group type: EXPERIMENTAL
Intervention: Exercise Treadmill Testing (ETT)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Stress Imaging
Number of subjects: 212

Group type: COMPARATOR
Intervention: Routine Hospital Admission
Number of subjects: 212
Study: 12081816

Group type: EXPERIMENTAL
Intervention: Ground beef with 2.7 g of phytosterols
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ground beef alone (control)
Number of subjects: 34
Study: 9607230

Group type: EXPERIMENTAL
Intervention: Step-by-step training with feedback, using role-play and video-recording (experimental)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-administered teaching programme (self-training)
Number of subjects: 20
Study: 7634863

Group type: EXPERIMENTAL
Intervention: Thoracic drainage (TD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Needle aspiration (NA)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Immediate needle aspiration (NA)
Number of subjects: 61
Study: 1495689

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6431853

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30702374

Group type: EXPERIMENTAL
Intervention: CHO mouth rinse (maltodextrin, 6%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (industrialized noncaloric juice with the same taste)
Number of subjects: 10
Study: 29530346

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery with intraperitoneal chemotherapy (CRS + IPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 0
Study: 27649961

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 660 nm, spatial average energy fluency (SAEF) = 1.06 J/cm2, applied on postoperative days 2, 4, 6, and 8.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo treatment (details not specified).
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 90
Study: 24315980

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks, two supervised and one self-instructed session per week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training for 12 weeks, two supervised and one self-instructed session per week.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without specific physical training, receiving respiratory therapy over 12 weeks.
Number of subjects: 0
Study: 22475741

Group type: EXPERIMENTAL
Intervention: Aerosolized fluticasone 880 μg twice daily for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo inhaler twice daily for 6 weeks
Number of subjects: 42
Study: 20576092

Group type: EXPERIMENTAL
Intervention: Combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone (FIN‐RACo)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Single DMARD (initially, sulfasalazine) with or without prednisolone (SINGLE)
Number of subjects: 199
Study: 17611823

Group type: EXPERIMENTAL
Intervention: Written educational material
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo material (2 leaflets about childproofing the house)
Number of subjects: 378
Study: 15629211

Group type: EXPERIMENTAL
Intervention: Covert visual attention task for adults with dyslexia
Number of subjects: 0
Study: 12406334

Group type: EXPERIMENTAL
Intervention: 20 mg pimecrolimus twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg pimecrolimus twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: pimecrolimus
Number of subjects: 0
Study: 9411958

Group type: EXPERIMENTAL
Intervention: Preventive home visits by health care personnel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 8217026

Group type: EXPERIMENTAL
Intervention: lisinopril or isradipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 3121861

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride, 225-450 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride
Number of subjects: 60
Study: 29700636

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with hematopoietic stem cell rescue, modified regimen including melphalan, carboplatin, and etoposide.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (initial regimen before modification).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Modified high-dose chemotherapy regimen.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients younger than 547 days and those with whole chromosomal gains/losses pattern.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MYCN amplification cases.
Number of subjects: 50
Study: 27377612

Group type: EXPERIMENTAL
Intervention: Local wound care interventions (specific interventions not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cochrane review findings
Number of subjects: 0
Study: 24925270

Group type: EXPERIMENTAL
Intervention: MD supplemented with 50mL/d of extra virgin olive oil (MD+EVOO)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: MD supplemented with 30 g/d of nuts (MD+Nuts)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 164
Study: 23218622

Group type: EXPERIMENTAL
Intervention: Minimally invasive approach (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional anterolateral approach (group B)
Number of subjects: 40
Study: 20724431

Group type: EXPERIMENTAL
Intervention: i.v. cyclophosphamide (CYC) 0.5 g/m2 at 4-week intervals with low-dose prednisolone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-dose prednisolone alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: i.v. CYC and prednisolone in disease controls
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EPC responders (CYC group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EPC non-responders (CYC group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CYC group
Number of subjects: 12
Study: 19005196

Group type: EXPERIMENTAL
Intervention: Active stimulation of the subthalamic nucleus
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study: 15728070

Group type: EXPERIMENTAL
Intervention: Oral clonidine 100 microg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 12637258

Group type: EXPERIMENTAL
Intervention: Sustained hyperglycemia (glucose concentration approximately 7.0 mM)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postprandial glucose profile (glucose peaked at 11.2 ± 0.5 mmol/l)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Euglycemia (glucose clamped at approximately 5.3 mM)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sustained hyperglycemia and postprandial profile
Number of subjects: 31
Study: 10791184

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (Laparoscopic and Open)
Number of subjects: 70
Study: 8852389

Group type: EXPERIMENTAL
Intervention: 40 mg sematilide HCl intravenous infusion over 30 minutes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 100 mg sematilide HCl tablet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous and oral administration of sematilide HCl
Number of subjects: 22
Study: 1399032

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg daily for 14 weeks)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Beta-carotene (after intervention)
Number of subjects: 123
Study: 3893014

Group type: EXPERIMENTAL
Intervention: Diazepam 0.08 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: d‐tubocurarine 0.05 mg/kg
Number of subjects: 30
Study: 31427688

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (standard preventive measures)
Number of subjects: 222
Study: 30265691

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (daily multi-strain capsule containing Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium lactis Bi-07, Bifidobacterium lactis B1-04)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27215976

Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (20-60 mg/day or 80-120 mg/day)
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy (20-120 mg/day)
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy
Number of subjects: 825
Study: 25002297

Group type: EXPERIMENTAL
Intervention: Complete set of 60 cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consensus set with agreement among experienced graders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consensus set compared to complete set
Number of subjects: 0
Study: 22588803

Group type: EXPERIMENTAL
Intervention: Tai chi classes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Time-matched education control
Number of subjects: 100
Study: 20211295

Group type: EXPERIMENTAL
Intervention: Autologous early endothelial progenitor cells (EPCs)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: E-CMMs transfected with human endothelial nitric oxide synthase
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (Plasma-Lyte A)
Number of subjects: 99
Study: 18569274

Group type: EXPERIMENTAL
Intervention: Silica gel
Number of subjects: 74

Group type: COMPARATOR
Intervention: Acyclovir cream
Number of subjects: 74
Study: 15759526

Group type: EXPERIMENTAL
Intervention: Lower leg casting plus injections with botulinum toxin (group III)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lower leg casting plus injections with saline (group II)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Current physical treatment (group I)
Number of subjects: 35
Study: 11831530

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention designed to improve the attitude and behavior of stockpeople toward cows
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control treatment (no intervention)
Number of subjects: 123
Study: 9920138

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at supraphysiological dosages (up to 8 IU/m2/d) for 4 years in the dose-response study.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a total dose of 6 IU/m2/d with low-dose ethinyl estradiol (50 ng/kg/d orally) in once-daily (OD) and twice-daily (BID) injection regimens for 2 years in the frequency-response study.
Number of subjects: 87

Group type: COMPARATOR
Intervention: Comparison with healthy Dutch control subjects in the dose-response study.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Increasing GH dosage in the dose-response study.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: GH treatment at supraphysiological dosages.
Number of subjects: 87
Study: 7755523

Group type: EXPERIMENTAL
Intervention: Cognitive Analytical Therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Educational Behavioral Treatment
Number of subjects: 30
Study: 2271377

Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride (0.5, 1, and 2 micrograms kg‐1 s.c.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 355663

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine hydrochloride (10 mg three times a day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg three times a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31721005

Group type: EXPERIMENTAL
Intervention: Barriers to engaging ethnic minorities and families receiving social services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitators for engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organizational culture
Number of subjects: 0
Study: 31009099

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (n=45)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Systematic reviews (n=30)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Outcome studies of root canal treatment (n=35)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Articles published in the Journal of Endodontics (n=70)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Articles published in the International Endodontic Journal (n=27)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Meta-analysis (n=23)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Systematic review (n=23)
Number of subjects: 100
Study: 28385185

Group type: EXPERIMENTAL
Intervention: BoNT/A (BOTOX®, Allergan) tri-annually
Number of subjects: 38

Group type: COMPARATOR
Intervention: BoNT/A (BOTOX®, Allergan) annually
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BoNT/A (BOTOX®, Allergan) tri-annually and annually
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Caucasian patients treated with BoNT/A
Number of subjects: 38
Study: 25616430

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC of 6 on day 1 and nab-paclitaxel 300 mg/m(2) on day 1 every 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC of 6 on day 1 and nab-paclitaxel 100 mg/m(2) on days 1, 8, and 15 every 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24063840

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Both R-ZES and SES
Number of subjects: 256
Study: 20410682

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (31 specific interventions including individual counselling and group sessions)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Control group (7 newsletters providing health information and results of health checkups)
Number of subjects: 549